Pharmaceutical microbiology testing for non-sterile and sterile drug products, raw materials, packaging and environmental monitoring samples. Methods aligned to USP <61>, <62>, <71>, <85> and the Ph. Eur. equivalents, supported by media fertility checks, growth-promotion testing and method suitability.
Microbial enumeration / bioburden (TAMC, TYMC)
Tests for specified microorganisms (E. coli, Salmonella, S. aureus, P. aeruginosa, others)
Sterility testing — membrane filtration and direct inoculation
Bacterial endotoxin testing (LAL — gel-clot, kinetic chromogenic)
Antimicrobial preservative-efficacy testing (PET / challenge test)
Method suitability / bacteriostasis-fungistasis verification
Environmental monitoring — surface, air and personnel
Identification of recovered isolates (16S / MALDI on referral)
Sterility testing of filterable products and large-volume parenterals.
Sterility for products that interfere with filtration.
TAMC and TYMC enumeration to USP <61>, Ph. Eur. 2.6.12.
Specified-organism testing per USP <62>, Ph. Eur. 2.6.13.
Quantitative endotoxin to USP <85>, Ph. Eur. 2.6.14.
Limit-test endotoxin where chromogenic interference is a risk.
USP <51>, Ph. Eur. 5.1.3 efficacy of antimicrobial preservation.
Methods, documentation and acceptance criteria are designed to align with the standards below. This describes design intent — formal accreditations are listed on the About page.
Microbial CoA per batch
Method suitability / validation report
Sterility test report with positive / negative controls
Endotoxin report (CSE certificate, lysate sensitivity, recovery)
PET study report with log-reduction kinetics
Trended environmental-monitoring data with action / alert flags
Send a short scope and we'll come back with a quote and indicative timeline within one working day.